Dmytro Kharkov

Solid Biosciences Inc. targets platform partnerships at BIO2026 in San Diego

Solid Biosciences Inc. targets platform partnerships at BIO2026 in San Diego
Solid Biosciences at BIO2026

Solid Biosciences Inc. is preparing to engage with industry peers and potential partners at the upcoming BIO2026 conference in San Diego. The company is encouraging participants in the genetic medicine sector to initiate conversations around platform partnerships and its development pipeline.

This outreach underscores Solid Biosciences Inc.'s strategic focus on collaboration within the gene therapy and biotechnology innovation landscape. The company aims to foster new connections and discuss opportunities that may expand its presence and impact in the field.

Solid Biosciences Inc. recently presented clinical insights on its SGT-003 gene therapy candidate for Duchenne muscular dystrophy at a leading scientific congress, according to a company update. The firm also strengthened its relationship with the Jett Foundation as a sponsor of the organization’s 25th Anniversary Silver Soirée earlier this month, as noted in a prior announcement. These activities highlight Solid’s ongoing engagement within both the scientific and patient communities.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.